Injectable PrEP shot for HIV prevention in higher-risk adults
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be assigned male at birth (cisgender men, non-binary people assigned male, or transgender women and men) and be 18–30 years old
- Have had anal sex with a partner assigned male at birth within the last 6 months
- Be looking for PrEP (HIV prevention) and have not used cabotegravir LA or TDF/FTC PrEP before
- Have negative HIV testing at enrollment (both rapid test and, if using injectable cabotegravir, an undetectable HIV RNA test)
- Do not have significant liver problems and avoid certain medicines that can lower cabotegravir levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This study looks at the best ways to offer long-acting injectable PrEP (a shot to prevent HIV) in clinics. It involves clinic staff and a review of patient records to improve how this prevention option is delivered.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.